Early stroke and systemic embolism rates in patients following cardioversion for atrial fibrillation (A-fib) are low and comparable between those receiving warfarin or the novel oral anticoagulant ...

LISBON, Portugal—Patients presenting to the emergency department (ED) with new, symptomatic A-fib do not necessarily need to undergo immediate cardioversion, as is now common practice, the RACE 7 ...

Please provide your email address to receive an email when new articles are posted on . BARCELONA, Spain — Patients with nonvalvular atrial fibrillation undergoing elective cardioversion who were ...

The 2006 American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) Practice Guidelines for the Management of Atrial Fibrillation state that various benign ...

Warfarin, dabigatran and rivaroxaban are safe periprocedural anticoagulation options for patients undergoing cardioversion or ablation for atrial fibrillation, according to researchers in Canada. “We ...

The drug-shock strategy was more effective for patients experiencing atrial fibrillation for the first time and for patients younger than 70 years, the researchers said. Both the anti-arrhythmia drug ...

Cardioversion can improve heart function, reduce the risk of embolism and relieve symptoms in patients with atrial fibrillation. Despite anticoagulation therapy, thromboembolic complications can still ...

But the current study, from Dr Gaetano M De Ferrari (University of Pavia, Italy) and colleagues, suggests that there can be a role for cardioversion in some populations, in this case patients with ...

The oral anticoagulant rivaroxaban is a safe and effective alternative to vitamin K antagonists for patients with atrial fibrillation (AF) undergoing cardioversion. This finding from the X-VeRT trial ...

Medtronic alerted healthcare professionals in Europe to the risk of cardioversion-related damage to the Vanta implantable neurostimulator (INS), model 977006, During cardioversion, healthcare workers ...